Class summary at a glance.

Every drug in the Alkylating Drug class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 16tracked in Part D
CY24 Part D spend: $64.9Mcombined across class
Total Rx claims: 20K6K unique beneficiaries
Generic mfrs (active): 77across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Mechlorethamine

Brand: VALCHLOR · 3K Part D claims (CY24) · 933 beneficiaries · First FDA approval: 2018-11-08

Brand-only (no generics) 316 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $22.1M

Class share

34%

of class CY24 spend

View profile →

Chlorambucil

Brand: LEUKERAN · 1K Part D claims (CY24) · 241 beneficiaries · First FDA approval: 2023-05-15

Brand-only (no generics) 73 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $19.9M

Class share

31%

of class CY24 spend

View profile →

Bendamustine

Brand: BELRAPZO · 1K Part D claims (CY24) · 344 beneficiaries · First FDA approval: 2008-03-31

4 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend $7.9M

Class share

12%

of class CY24 spend

View profile →

Lomustine

Brand: Gleostine · 5K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2014-08-18

1 generic mfrs 168 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $5.9M

Class share

of class CY24 spend

View profile →

Lurbinectedin

Brand: ZEPZELCA · 264 Part D claims (CY24) · 77 beneficiaries · First FDA approval: 2020-06-15

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $3.9M

Class share

of class CY24 spend

View profile →

Cyclophosphamide

Brand: Frindovyx · 9K Part D claims (CY24) · 3K beneficiaries · First FDA approval: 2008-05-21

14 generic mfrs 576 plans require PA

Low NADAC$1.12

→

Avg plan cost$1.41

Part D spend $3.1M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Trabectedin

Brand: YONDELIS · 120 Part D claims (CY24) · 24 beneficiaries · First FDA approval: 2015-10-23

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $1.1M

Class share

of class CY24 spend

View profile →

Mitomycin

Brand: JELMYTO · 510 Part D claims (CY24) · 288 beneficiaries · First FDA approval: 1996-05-01

6 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend $674052

Class share

of class CY24 spend

View profile →

Busulfan

Brand: BUSULFEX · 16 Part D claims (CY24) · First FDA approval: 1999-02-04

8 generic mfrs Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $176645

Class share

of class CY24 spend

View profile →

Temozolomide

Brand: TEMODAR · 87 Part D claims (CY24) · 18 beneficiaries · First FDA approval: 1999-08-11

10 generic mfrs

Low NADAC$1.90

→

Avg plan cost$7.11

Part D spend $68822 4× spread, current vs floor

Class share

of class CY24 spend

View profile →

Melphalan

Brand: EVOMELA · 28 Part D claims (CY24) · First FDA approval: 2013-01-10

12 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend $3267

Class share

of class CY24 spend

View profile →

Dacarbazine

34 Part D claims (CY24) · First FDA approval: 2001-08-08

3 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend $2019

Class share

of class CY24 spend

View profile →

Carmustine

Brand: Gliadel · — Part D claims (CY24) · First FDA approval: 2012-12-13

7 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Ifosfamide

Brand: IFEX · — Part D claims (CY24) · First FDA approval: 1988-12-30

3 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Streptozocin

Brand: Zanosar · — Part D claims (CY24) · First FDA approval: 2025-07-10

Brand-only (no generics) Active FDA shortage

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Thiotepa

Brand: TEPADINA · — Part D claims (CY24) · First FDA approval: 2001-06-01

9 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.